Search research articles
Contact Us
Filters
Showing results (171-180 of 180) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 180 results.
Journal of Neurochemistry
|
February 29, 2000
Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia
S L Yates, L H Burgess, J Kocsis-Angle, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes
M J Thomassen, J M Antal, M J Connors, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 11, 2005
P boutons in lamina IX of the rodent spinal cord express high levels of glutamic acid decarboxylase-65 and originate from cells in deep medial dorsal horn
D I Hughes, M Mackie, G G Nagy, et al.
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
Investigational New Drugs
|
December 29, 2010
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist
John W Bauman, Joyce M Antal, Laurel M Adams, et al.
International Journal of Cancer
|
December 21, 2020
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Davey Daniel, Vladimer Kuchava, Igor Bondarenko, et al.
Advances in Therapy
|
October 30, 2020
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L Hart, Renata Ferrarotto, Zoran G Andric, et al.
Investigational New Drugs
|
April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Lancet. Oncology
|
October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R Tan, Gail S Wright, Anu R Thummala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J M Weiss, T Csoszi, M Maglakelidze, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 180) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 180 results.
Journal of Neurochemistry
|
February 29, 2000
Amyloid beta and amylin fibrils induce increases in proinflammatory cytokine and chemokine production by THP-1 cells and murine microglia
S L Yates, L H Burgess, J Kocsis-Angle, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes
M J Thomassen, J M Antal, M J Connors, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 11, 2005
P boutons in lamina IX of the rodent spinal cord express high levels of glutamic acid decarboxylase-65 and originate from cells in deep medial dorsal horn
D I Hughes, M Mackie, G G Nagy, et al.
Cancer Management and Research
|
August 19, 2021
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
Maen Hussein, Marina Maglakelidze, Donald A Richards, et al.
Investigational New Drugs
|
December 29, 2010
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist
John W Bauman, Joyce M Antal, Laurel M Adams, et al.
International Journal of Cancer
|
December 21, 2020
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Davey Daniel, Vladimer Kuchava, Igor Bondarenko, et al.
Advances in Therapy
|
October 30, 2020
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L Hart, Renata Ferrarotto, Zoran G Andric, et al.
Investigational New Drugs
|
April 4, 2018
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian, Katherine M Bell-McGuinn, Howard A Burris, et al.
The Lancet. Oncology
|
October 3, 2019
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R Tan, Gail S Wright, Anu R Thummala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J M Weiss, T Csoszi, M Maglakelidze, et al.
Page
of 18